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Abstract.  
Traceability is central to medical device software  development and essential for 
regulatory approval. To achieve compliance an effective traceability process needs 
to be in place. This is difficult to achieve due to the lack of specific guidance which 
the medical device regulations and standards provides. This has resulted in many 
medical device companies employing inefficient software traceability processes. In 
this paper we briefly outline the development and implementation of Med-Trace a 
lightweight software traceability process assessment and improvement method for 
the medical device industry.  
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1.   Introduction 
The important role that software plays in medical devices continues to increase.  
This has taken place in conjunction with the demand for increased medical device 
functionality. As a result of both of these factors the complexity of medical device 
software and its development has also increased [1]. This has necessitated the 
requirement for effective traceability and risk management processes and tools to be 
put in place to facilitate the development of medical device software.  
Medical device companies must ensure that they comply with medical device 
regulations as governed by the region in which they wish to market their device. If a 
device is to be marketed in Europe the medical device should be developed using 
processes that comply with the European Council’s Medical Device Directive (MDD) 
(1993/42/EEC) [2]  and amendment MDD (2007/47/EC) [3]. When a medical device 
is to be marketed in the United States (US) the medical device should be developed 
using processes that comply with the Food and Drug Administration (FDA) 
guidelines. In both locations the medical device companies must be able to produce 
sufficient evidence to support their product’s compliance.   
In addition to achieve compliance national regulatory requirements also recommend 
conformance to a number of international standards which include: IEC 62304:2006 
[4],  ISO 14971:2007 [5], ISO 13485:2003 [6] and  IEC 62366:2007 [7].  Given the 
need to address the requirements of national regulations and international standards 
software medical device companies are focused on compliance. While this is 
essential to market their products it has resulted in a lack of emphasis on process 
improvement and the achievements of its associated benefits [8].  
2   Software Traceability 
Software traceability refers to the ability to describe and follow the life of a 
requirement in both a forward and backward direction. This includes from its origins, 
specification, development, subsequent deployment and use and through periods of 
on-going refinement and iteration in any of these phases. The deployment of an 
effective traceability process is essential to facilitate the development of high quality 
software systems [9]. Therefore software traceability is key and  central to medical 
device software development and essential for regulatory compliance.    
In order to comply with the regulatory requirements of the medical device industry it 
is necessary to have clear linkages and traceability from requirements - including 
risks and hazards - through the different stages of the software development and 
maintenance lifecycles.  The regulatory bodies request that medical device software 
development organizations clearly demonstrate how they follow a software 
development lifecycle without mandating a particular lifecycle. This is further 
compounded by the requirement to adhere to numerous standards without guidance 
on how they should be implemented.  Given the lack of guidance and importance 
that traceability plays in medical device software development it was recognized that 
this was an important area which needed to be addressed.  The authors decided to 
tackle this important issue by developing a lightweight assessment method called 
Med-Trace, specifically to assist companies to adhere to the traceability aspects of 
the medical device software standards and regulations and also to improve their 
process. 
 
 
3   Med-Trace and Observations from Two Assessments 
Based on the results from an extensive literature review, the relevant areas of the  
CMMI® [10], ISO/IEC 15504-5:2006 [11] and previous experience of developing 
lightweight process assessment methods Med-Trace has been developed. Med-
Trace is a lightweight assessment method that provides a means of assessing the 
capability of an organization in relation to medical device software traceability. It 
enables software development organizations to gain an understanding of the 
fundamental traceability best practices based on the software engineering 
traceability literature, software process models, and the relevant medical device 
regulations and standards. Med-Trace may be used to diagnose an organization’s 
strengths and weaknesses in relation to their medical device software development 
traceability practices. The goal of a Med-Trace assessment is not certification, but to 
assist medical device organizations to improve their software development 
traceability process.  
The Med-Trace assessment method contains eight specific stages. The assessment 
team normally consists of two assessors who share responsibility for conducting the 
assessment.  Stage 1, a preliminary meeting between the assessment team and the 
company wishing to undergo a Med-Trace assessment takes place.  During stage 2, 
the lead assessor provides an overview of the Med-Trace assessment to members 
of the organization. At stage 3 a review is undertaken of project documentation.  
Staff from the organization with responsibility for traceability are interviewed at stage 
4. At stage 5 the assessors jointly develop the findings report. Stage 6 involves 
presenting the findings report. Stage 7 is the collaborative development of a pathway 
towards achieving highly effective and regulatory compliant traceability practices.  
Having participated in the development of this pathway the organization are 
responsible for its implementation. Stage 8 involves revisiting and reassessing the 
company approximately 3 months after the completion of stage 7 and reviewing 
progress against the recommended improvement path, a final report is also 
produced. 
Two Med-Trace assessments have taken place. The first was in an Irish medical 
device organization, Medical Electronic (a pseudonym). Medical Electronic develop 
electronic based medical devices that are marketed in the US and Europe.  The 
company recognized the importance traceability plays in medical device software 
development and they sought a lightweight assessment method to obtain guidance 
as to how they could improve their traceability process.  The second assessment 
took place in North Medical UK (a pseudonym). The company develop electronic-
based medical devices that require compliance with both the FDA and the MDD. 
North Medical UK also sought a resource-light assessment method to obtain 
guidance as to how they could improve their software development traceability 
process.   
As a result of both assessments it was clear the organizations recognized the 
importance traceability plays in medical device software development. This was 
reflected in the fact that in each, a member of the management team was 
responsible for its implementation.  The lack of detailed guidance on how to 
implement traceability was highlighted by the management of Medical Electronic and 
North Medical UK. While these organizations both employed a process for 
traceability, in each case these needed to be improved and formalized.  The 
requirement for relevant training and the ability to record and leverage best practice 
with regard to traceability emerged.  The serious limitations of utilizing manual tools 
such as MS Office to manage traceability was also recognized and needed to be 
addressed by both organizations. 
The findings from the assessments identified important areas where improvements 
were required and these were confirmed in consultation with the management and 
staff of both organizations. The adoption of the development pathway provided 
realistic goals and the collaborative process provided motivation for their 
achievement.  Both organizations are implementing their respective development 
pathways and have agreed to be reassessed as part of stage 8 of the Med-Trace 
assessment method. 
 
4   Conclusions 
In this paper we have presented Med-Trace a resource light process assessment 
method for the medical device software industry that can pinpoint specific areas for 
improvement with regard to traceability. We will continue to refine Med-Trace based 
on the experience gained in undertaking future assessments, interaction with 
medical device software organizations and discussions with medical device 
regulatory bodies. It is envisaged that further research will be undertaken for the 
development of similar lightweight software process assessment methods in the 
future. 
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